172@29@17@105!~!172@29@0@53!~!|news|business|astrazeneca-merck-lynparza-wins-european-union-approval-for-pancreatic-cancer-5522391.html!~!|controller|infinite_scroll_article.php
Moneycontrol
Financial Freedom Offer: Subscribe to Moneycontrol Pro and grab benefits worth ₹15,000/-
you are here: HomeNewsBusiness
Last Updated : Jul 08, 2020 12:30 PM IST | Source: Reuters

AstraZeneca-Merck Lynparza wins European Union approval for pancreatic cancer

The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.

Reuters

AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.
First Published on Jul 8, 2020 12:15 pm
Sections